JERUSALEM, September 20, 2017 /PRNewswire/ --
Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that
management will participate in the Ladenburg Thalmann 2017
Healthcare Conference to be held September
26, 2017 at the Sofitel Hotel in New York City.
Date and Time of
Presentation: Tuesday, September 26, 2017 at
3:00 p.m. Eastern time
Venue: Sofitel New York Hotel
Format: Company presentation
Presenter: Jeffrey A. Meckler, Chief Executive
Officer of Intec Pharma
Mr. Meckler's presentation will be webcast live and can be
accessed on the Events section of the Company's website at
http://www.intecpharma.com.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is being developed for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients, and
AP-CBD/THC, an Accordion Pill with the two primary cannabinoids
contained in Cannabis sativa, cannabidiol (CBD) and
tetrahydrocannabinol (THC), which is being developed for various
indications including low back neuropathic pain and
fibromyalgia.
Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com
Anne Marie Fields
Senior Vice President
LHA Investor Relations
+1-212-838-3777
afields@lhai.com
SOURCE Intec Pharma Ltd.